ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Instituto de Biología Molecular y Celular (IBMC), and Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universitas Miguel Hernández, Elche, Spain.
Diabetologia. 2019 Mar;62(3):459-472. doi: 10.1007/s00125-018-4782-0. Epub 2018 Nov 26.
AIMS/HYPOTHESIS: The initial stages of type 1 diabetes are characterised by an aberrant islet inflammation that is in part regulated by the interaction between type 1 diabetes susceptibility genes and environmental factors. Chromosome 16p13 is associated with type 1 diabetes and CLEC16A is thought to be the aetiological gene in the region. Recent gene expression analysis has, however, indicated that SNPs in CLEC16A modulate the expression of a neighbouring gene with unknown function named DEXI, encoding dexamethasone-induced protein (DEXI). We therefore evaluated the role of DEXI in beta cell responses to 'danger signals' and determined the mechanisms involved.
Functional studies based on silencing or overexpression of DEXI were performed in rat and human pancreatic beta cells. Beta cell inflammation and apoptosis, driven by a synthetic viral double-stranded RNA, were evaluated by real-time PCR, western blotting and luciferase assays.
DEXI-silenced beta cells exposed to a synthetic double-stranded RNA (polyinosinic:polycytidylic acid [PIC], a by-product of viral replication) showed reduced activation of signal transducer and activator of transcription (STAT) 1 and lower production of proinflammatory chemokines that was preceded by a reduction in IFNβ levels. Exposure to PIC increased chromatin-bound DEXI and IFNβ promoter activity. This effect on IFNβ promoter was inhibited in DEXI-silenced beta cells, suggesting that DEXI is implicated in the regulation of IFNβ transcription. In a mirror image of knockdown experiments, DEXI overexpression led to increased levels of STAT1 and proinflammatory chemokines.
CONCLUSIONS/INTERPRETATION: These observations support DEXI as the aetiological gene in the type 1 diabetes-associated 16p13 genomic region, and provide the first indication of a link between this candidate gene and the regulation of local antiviral immune responses in beta cells. Moreover, our results provide initial information on the function of DEXI.
目的/假设:1 型糖尿病的初始阶段表现为胰岛炎症异常,部分受 1 型糖尿病易感基因与环境因素相互作用的调节。16p13 染色体与 1 型糖尿病相关,而 CLEC16A 被认为是该区域的致病基因。然而,最近的基因表达分析表明,CLEC16A 中的 SNP 调节了具有未知功能的相邻基因 DEXI 的表达,该基因编码地塞米松诱导蛋白(DEXI)。因此,我们评估了 DEXI 在β细胞对“危险信号”反应中的作用,并确定了相关机制。
在大鼠和人胰岛β细胞中进行基于 DEXI 沉默或过表达的功能研究。通过实时 PCR、western blot 和荧光素酶测定评估由合成的病毒双链 RNA 驱动的β细胞炎症和凋亡。
暴露于合成双链 RNA(多聚肌苷酸:多聚胞苷酸[PIC],病毒复制的副产物)的 DEXI 沉默的β细胞显示 STAT1 的激活减少,促炎趋化因子的产生降低,这是 IFNβ 水平降低的结果。PIC 暴露增加了染色质结合的 DEXI 和 IFNβ 启动子活性。这种对 IFNβ 启动子的影响在 DEXI 沉默的β细胞中被抑制,表明 DEXI 参与了 IFNβ 转录的调节。在与敲低实验相反的镜象实验中,DEXI 过表达导致 STAT1 和促炎趋化因子水平升高。
结论/解释:这些观察结果支持 DEXI 作为 16p13 基因组区域与 1 型糖尿病相关的致病基因,并首次表明该候选基因与β细胞中局部抗病毒免疫反应的调节之间存在联系。此外,我们的结果提供了 DEXI 功能的初步信息。